Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE Cervical
jRCT2031230436Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Volrustomig with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2023; status: recruiting.
02
Drugs
volrustomig
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2031230436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230436.